checkpoint inhibitors Archives
New prostate cancer treatment concept
Aug. 22, 2019—Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.
Encephalitis identified as rare toxicity of immunotherapy treatment
Jul. 22, 2019—Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.
Discovery points to new cancer immunotherapy option
Feb. 21, 2019—An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.
Breast cancer-killing RIG
Dec. 13, 2018—A compound that activates a virus-sensing receptor has potent therapeutic effects in a mouse model of breast cancer.
Immunotherapies linked to specific heart complications
Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.
Study tracks incidence, timing of immunotherapy-related deaths
Sep. 13, 2018—Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.
